Contents

November 2018 Volume 27 Issue S1

Commentaries
s1 Heated tobacco products: the example of IQOS
S A Glantz
s7 Heated tobacco products: things we do and do not know
I Stepnov, A Woodward

Research papers
s9 PMI’s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes
S A Glantz
s13 Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke
P Nabakowitci, J Liu, C M Havel, S Ibrahim, R Deraishian, P Jacob III, M L Springer
s20 Assessment of industry data on pulmonary and immunosuppressive effects of IQOS
F Aloazed, L Chun, M A Manthey, C S Calfee, J Gotts
s30 IQOS: examination of Philip Morris International’s claim of reduced exposure
G St Helen, P Jacob III, N Nardone, N L Benowitz
s41 Heated tobacco products likely appeal to adolescents and young adults
K McKelvey, L Popova, M Kim, B W Chaffee, M Vijayaraghavan, P Ling, B Halpern-Felsher
s48 IQOS labelling will mislead consumers
K McKelvey, L Popova, M Kim, L K Lemper, B W Chaffee, M Vijayaraghavan, P Ling, B Halpern-Felsher
s55 Awareness and use of heated tobacco products among US adults, 2016–2017
A L Nyman, S R Weaver, L Popova, T F Peuchacek, J Huang, D L Ashley, M P Erikson
s62 Impact of modified risk tobacco product claims on beliefs of US adults and adolescents
S El-Toukhy, S A Baig, M Jeong, M J Byron, K M Rübs, N T Brewer
s70 Examining perceptions about IQOS heated tobacco product: consumer studies in Japan and Switzerland
E C Hair, M Bennett, E Sheen, J Canterell, J Briggs, Z Fen, J G Willen, D Vallone

s82 Modelling the impact of a new tobacco product: review of Philip Morris International’s Population Health Impact Model as applied to the IQOS heated tobacco product
W B Max, H-Y Sung, J Lightwood, Y Wang, T Yao
s87 Light and mild redux: heated tobacco products’ reduced exposure claims are likely to be misunderstood as reduced risk claims
I Popova, L K Lemper, S A Glantz
s96 Invisible smoke: third-party endorsement and the resurrection of heat-not-burn tobacco products
J Elias, P M Ling
s102 Revolution or redux? Assessing IQOS through a precursor product
J Elias, V M Dutra, G St Helen, P M Ling

Brief reports
s26 Cytotoxic effects of heated tobacco products (HTP) on human bronchial epithelial cells
N J Leigh, P L Tran, R J O’Connor, M L Goniewicz
s74 Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults
J Kim, H Yu, S Lee, Y J Park

Research letters
s37 Tobacco-specific nitrosamines (TSNA) in heated tobacco product IQOS
N J Leigh, M N Palumbo, A M Marno, R J O’Connor, M L Goniewicz
s39 Possible hepatotoxicity of IQOS
L Chun, F Aloazed, M Manthey, C Calfee, J Gotts

Industry watch
s78 IQOS campaign in Israel
I J Rosen, S Kislev

Special communication
s111 Heated tobacco products: another tobacco industry global strategy to slow progress in tobacco control
S A Bialous, S A Glantz
s118 Heated tobacco product regulation under US law and the FCTC
L K Lemper, S A Glantz